根治性放疗作为新诊断IVB期宫颈癌伴同时性寡转移原发灶和转移灶的首选治疗策略
该回顾性研究纳入60例新诊断IVB期宫颈癌伴同时性寡转移患者,均接受原发灶和转移灶根治性放疗(VMAT或IMRT后三维腔内/组织间近距离治疗)。5年总生存率51.4%,5年无进展生存率25.9%,中位无进展生存期52.3个月,中位总生存期未达到。淋巴转移较血行转移、1个转移部位较≥2个转移部位、治疗前肿瘤直径≤4cm者预后更优。
要点
- 60例IVB期宫颈癌伴同时性寡转移患者接受原发灶和转移灶根治性放疗,5年OS率51.4%,5年PFS率25.9%。
- 淋巴转移者3年OS率57.2%优于血行转移者20%(p=0.017)。
- 1个转移部位者3年OS率60.4%优于≥2个转移部位者20.6%(p=0.003)。
核心结论
- 对经选择的IVB期宫颈癌伴寡转移患者,原发灶和寡转移灶根治性放疗是可行的治疗策略。
- 转移类型、转移部位数目和治疗前肿瘤直径是显著的预后因素。
- 新辅助化疗、淋巴结转移类型(锁骨上或腹股沟)和淋巴转移部位数目未达统计学显著预后因素。
研究设计与样本
- 回顾性纳入2014年7月至2020年12月在本机构接受根治性放疗的60例新诊断IVB期宫颈癌患者。
- 所有患者基于FIGO 2018指南分期,原发灶和转移灶均接受VMAT或IMRT后三维腔内/组织间近距离治疗。
- 分析总生存期、无进展生存期及患者预后因素。
主要发现
- 60例接受根治性放疗患者5年OS率51.4%,5年PFS率25.9%。
- 中位PFS为52.3个月,中位OS未达到。
- 淋巴转移者3年OS率57.2% vs 血行转移者20%(p=0.017)。
- 1个转移部位者3年OS率60.4% vs ≥2个转移部位者20.6%(p=0.003)。
- 治疗前肿瘤直径>4cm者5年OS率41.2% vs ≤4cm者65.2%(p=0.029),5年PFS率10.4% vs 53.7%(p=0.021)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The present study identified survival and progression-free rates and evaluated prognostic factors for IVB stage cervical cancer in patients that presented with synchronous oligometastases (sync-oligometastases) who received definitive irradiation for primary and metastatic sites. METHODS: The study retrospectively included 60 patients with newly diagnosed stage IVB cervical cancer. Patients received definitive radiation for both primary and metastatic sites through Volumetric Modulated Arc Therapy (VMAT) or intensity modulated radiation therapy (IMRT) followed by three dimensional-intracavitary/interstitial brachytherapy at our institution between July 2014 to December 2020. All patients were staged based on the International Federation of Gynecology and Obstetrics (FIGO) 2018 guidelines. Overall survival (OS), progression-free survival (PFS), and patient prognostic factors were analyzed. RESULTS: The 60 patients who received curative-intent irradiation for primary and metastatic sites showed a 5-year OS rate of 51.4% and a 5-year PFS rate of 25.9%. The median PFS was 52.3 months, and the median OS had not been reached. Lymphatic metastases had a better OS compared with hematogenous metastases (3-year OS rates: 57.2% vs. 20%, p = 0.017). Patients with one metastasis site showed a more favorable prognosis than patients with ≥ 2 metastases sites (3-year OS rates: 60.4% vs. 20.6%, p = 0.003). Patients that presented with tumors larger than 4 cm in diameter before treatment demonstrated a poorer prognosis (5-year OS rates: 41.2% vs. 65.2%, p = 0.029; 5-year PFS rates: 10.4% vs. 53.7%, p = 0.021). CONCLUSION: Definitive irradiation for both primary and oligo-metastatic sites for selected IVB patients is a feasible treatment strategy. Metastatic type, number of metastatic sites, and pre-treatment tumor diameter were significant prognostic factors. Neoadjuvant chemotherapy, the lymph nodal metastatic type (supraclavicular or inguinal), and number of lymphatic metastatic sites failed to reach statistical significance as prognostic factors.
引用
- Li J, Wang Y, Huo L, et al. Definitive irradiation as a first treatment strategy for primary and metastatic sites of newly diagnosed IVB cervical cancer that presented with synchronous oligometastases. Radiat Oncol. 2023. PMID: 37752606. doi:10.1186/s13014-023-02320-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。